Phase 2 N=188 Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and Chemotherapy
Abdominal Neoplasm · Colonic Neoplasm · Mesothelioma
Primary: Number of Participants With Disease-free Survival
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=30 Debulking and Chemotherapy With or Without Intraperitoneal Chemotherapy to Treat Peritoneal Carcinomatosis
Gastrointestinal Neoplasm
Primary: Progression Free Survival
Phase 2 N=51 HIPEC for Peritoneal Carcinomatosis
Peritoneal Carcinomatosis · Colorectal Cancer · Appendiceal Cancer
Primary: Completeness of Cytoreduction
Phase 2 N=21 Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis
Gynecologic Cancer · Gynecologic Neoplasms · Peritoneal Carcinomatosis
Primary: Proportion of Participants Who Are Successfully Down Staged to Resectable Based on Peritoneal Carcinomatosis Index (PCI) and Principal Investigator (PI) Discretion…
Phase 2 N=19 Laparoscopic Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) for Metastatic Gastric Cancer
Gastrointestinal Cancer
Primary: Overall Survival (OS) After Hyperthermic Intraperitoneal Chemotherapy — 30.2 Months
Phase 1 N=15 Alimta® Plus Cisplatin & Paclitaxel Given Intraperitonelly; First Line Tx Stage III Ovarian Cancer
Fallopian Tube Cancer · Ovarian Cancer · Peritoneal Cavity Cancer
Primary: Maximum-tolerated Dose of Pemetrexed With a Day 2 i.p. Cisplatin (75 mg/m2) and Day 8 i.p. Paclitaxel (60 mg/m2) — 500 mg/m2
Phase 2 N=43 Role of Intraperitoneal Intraoperative Chemotherapy With Paclitaxel in the Surgical Treatment of Peritoneal Carcinomatosis From Ovarian Cancer. Hyperthermia Versus Normothermia
Peritoneal Carcinomatosis
Primary: The Grouped Miller and Payne (MP) System for Pathological Response: G1 (Minimal Changes and < 30% Cells Tumour Reduction That Includes MP G1-G2), G3 (Microscopic Foci…
Phase 2 N=51 A Study to Evaluate ONM100, an Intraoperative Fluor Imaging Agent for the Detection of Peri Mets
Peritoneal Carcinomatosis
Primary: Percentage of Patients That Had at Least One Additional Lesion Detected Under Pegsitacianine Guidance Following CRS That Was Confirmed as Positive for Disease by…
Phase 1 N=18 Talimogene Laherparepvec for the Treatment of Peritoneal Surface Malignancies
Peritoneal Surface Malignancy
Primary: Dose Limiting Toxicity (DLT) — 0; 0; 0 Participants
Phase 2 N=27 Heated Intraperitoneal Chemotherapy and Gastrectomy for Gastric Cancer With Positive Peritoneal Cytology
Gastric Adenocarcinoma · Esophagogastric Junction · Gastric Cancer
Primary: Overall Survival (OS) — 11.96 Months
Phase 2 N=2 A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma
Mesothelioma · Peritoneal Mesothelioma
Primary: Major Pathologic (Disease) Response of Tumor to Nivolumab Combined With Ipilimumab Before Surgery
Phase 1 N=11 Phase I Study of Cantrixil in Patients With Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer.
Ovarian Neoplasms · Fallopian Tube Neoplasms · Peritoneal Neoplasms
Primary: Determination of the Maximum Tolerated Dose (MTD) — 0; 0; 0; 0 Participants
Phase 2 N=275 Intraperitoneal vs Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer
Fallopian Tube Cancer · Metastatic Cancer · Ovarian Cancer
Primary: 9-month Progression Rate Post-randomization — 0.386; 0.347; 0.245 Porportion of participants — p=0.065
Phase 3 N=1,560 Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Fallopian Tube Clear Cell Adenocarcinoma · Fallopian Tube Endometrioid Adenocarcinoma · Fallopian Tube Mucinous Adenocarcinoma
Primary: Median Progression-free Survival — 24.9; 27.3; 26.0 months — p=0.341
Phase 3 N=204 Adjuvant HIPEC in High Risk Colon Cancer
Colorectal Neoplasms · Peritoneal Neoplasms
Primary: Peritoneal Recurrence Free Survival at 18 Months — 79; 80 participants
Phase 2 N=112 Rapid Gastric and Pancreas Cancer Staging Utilizing Peritoneal Lavage
Gastric Cancer · Pancreatic Cancer
Primary: Number of Study Participants With Adequate Percutaneous Lavage Specimen Collection — 70; 2; 4 Participants
Phase 2 N=22 Pilot Study of Hyperthermic Peritoneal Perfusion (HIPEC) for Adolescent and Young Adults With Desmoplastic Small Round Cell Tumor
Advanced Cancers · Sarcoma
Primary: Recurrence Free Survival — 13.99 months
N/A N=60 SurgiPerito Trial: High-Purity Type-I Collagen for Peritoneal Reconstruction After Cytoreductive Surgery
Peritoneal Surface Malignancy · Postoperative Adhesion · Bowel Obstruction
Primary: Incidence of Major Intra-abdominal Complications — 4; 11 Participants
Phase 2 N=50 Hyperthermic Intraperitoneal Chemotherapy Trial Comparing Quality of Life in Patients With Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Stage IIIC Fallopian Tube Cancer · Stage IIIC Ovarian Cancer · Stage IIIC Primary Peritoneal Cancer
Primary: Quality of Life (QOL) Assessed Using Functional Assessment of Cancer Therapy-Ovarian Questionnaire (FACT-O) — 116.32 score on a scale
Phase 2 N=28 Trial of Chemotherapy in Ovarian, Fallopian Tube and Peritoneal Carcinoma
Primary Peritoneal Carcinoma · Ovarian Carcinoma · Fallopian Tube Carcinoma
Primary: Percentage of Patients That Achieve Maximal Surgical Debulking — 10 Participants
Phase 2 N=86 Trial of Pemetrexed and Carboplatin in Patients With Recurrent Ovarian or Primary Peritoneal Cancer
Ovarian Cancer · Primary Peritoneal Cancer
Primary: Phase 1 - Maximum Tolerated Dose (MTD) of Pemetrexed in Combination With Carboplatin
Phase 3 N=4,312 Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer
Primary Peritoneal Carcinoma · Stage III Ovarian Cancer · Stage IV Ovarian Cancer
Primary: Overall Survival — 0.35; 0.34; 0.39; 0.34 Proportion of participants
Phase 2 N=42 Intravenous and Intraperitoneal Paclitaxel, Intraperitoneal Cisplatin, and Intravenous Bevacizumab for the Initial Treatment of Optimal Stage II or III Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
Ovarian Cancer · Primary PERITONEUM · Fallopian Tube Cancer
Primary: Overall Objective Response — 10; 13; 11; 4 participants
Phase 2 N=38 Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian Primary Peritoneal Carcinoma
Ovarian Carcinoma · Primary Peritoneal Carcinoma
Primary: Progression-free Survival (PFS) — 56 percentage of participants
Phase 2 N=30 Papillary Serous Carcinoma of the Endometrium
Endometrial Cancer
Primary: Overall Survival at 2 Years and 5 Years — 93; 85 percentage of participants
Phase 2 N=260 Local mEHT + TCM Versus Intraperitoneal Chemoinfusion in Treatment of Malignant Ascites: Phase II RCT
Peritoneal Neoplasms · Ascites · Yang Deficiency
Primary: Objective Response Rate (ORR) — 77.7; 63.8 percentage of participants — p=0.0140
Phase 2 N=58 Bortezomib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
Primary Peritoneal Cavity Cancer · Recurrent Ovarian Epithelial Cancer
Primary: Tumor Response Duration — 3.9; 24.1 months
Phase 3 N=521 Trial of Adjuvant Chemotherapy for Gastric Cancer
Stomach Cancer
Primary: Relapse-free Survival — 50.0; 60.2 percentage of participants
Phase 2 N=136 Surgery and Oxaliplatin or Mitomycin C in Treating Patients With Tumors of the Appendix
Carcinoma of the Appendix · Primary Peritoneal Cavity Cancer
Primary: The Difference in the Number of Grade 3 or 4 Hematologic Toxicities (Leukopenia, Thrombocytopenia, and Neutropenia) Between the Mitomycin C and Oxaliplatin Treatments…
Phase 2 N=51 A Study of Single Agent Pemetrexed Disodium in Treating Patients With Recurrent or Persistent Ovarian or Primary Peritoneal Cancer
Ovarian Cancer · Peritoneal Cancer
Primary: Tumor Response — 1; 9; 17; 18 participants